Blueprint Medicines (NASDAQ:BPMC) Raised to “Hold” at StockNews.com
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Saturday. Other equities research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Saturday. Other equities research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines […]
